BioCardia (BCDA) Projected to Post Quarterly Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is projected to announce its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

BioCardia (NASDAQ:BCDA) last announced its earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share for the quarter. On average, analysts expect BioCardia to post $-4 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioCardia Stock Up 0.4%

NASDAQ:BCDA opened at $1.21 on Wednesday. The stock has a market cap of $12.79 million, a P/E ratio of -0.81 and a beta of 0.60. The business’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.35. BioCardia has a twelve month low of $1.00 and a twelve month high of $3.20.

BioCardia News Roundup

Here are the key news stories impacting BioCardia this week:

• Positive Sentiment: Management says an FDA submission for the CardiAMP therapy is imminent and highlights trial data that the company interprets as signaling clinical benefit — a clear regulatory catalyst if submission timing and data interpretation hold. BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit
• Positive Sentiment: Q4 2025 earnings call and accompanying coverage emphasize promising clinical results and plan milestones that could unlock value if regulatory interactions progress as described. Investors typically reward clear development timelines and positive clinical messaging. BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid …
• Positive Sentiment: Full earnings-call transcript provides management commentary on data, regulatory timing and next steps — useful for investors parsing whether upcoming catalysts are achievable. BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
• Positive Sentiment: Company filed its 2025 Form 10‑K and issued a business highlights release summarizing 2025 results and strategy — transparency and a formal filing reduce execution risk and help institutional investors confirm progress. BioCardia Reports 2025 Business Highlights and Financial Results
• Neutral Sentiment: Quarterly results showed an EPS loss (reported ($0.06) for the quarter); this is expected for a clinical-stage company and doesn’t materially change the valuation framework unless guidance or cash runway were updated. MarketBeat BCDA summary (EPS and trading data)
• Neutral Sentiment: Multiple short‑interest reports appear to show zero reported short positions and contain anomalous “NaN” changes — data seems unreliable, so there’s no clear sign of meaningful short pressure altering price action. (Repeated data entries.)
• Negative Sentiment: Risks remain: the company is still loss-making, has a small market cap and analyst estimates show negative EPS for the year — downside remains if clinical/regulatory milestones slip or if funding needs increase.

Institutional Trading of BioCardia

Several hedge funds have recently added to or reduced their stakes in BCDA. Cetera Investment Advisers purchased a new stake in BioCardia during the second quarter valued at about $40,000. DRW Securities LLC purchased a new stake in BioCardia during the 4th quarter valued at about $72,000. Finally, Geode Capital Management LLC boosted its holdings in BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after acquiring an additional 27,263 shares during the period. 20.57% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $25.00.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.